Commercially connected to CoreAge Rx. Read our disclosure ↗
← The reading listProvider review / Clinical care + nutrition support

Found GLP-1 review: digestive questions, follow-up and plan terms

Video or text-based care, 28-day plan costs and cancellation questions to settle before bringing digestive concerns to a provider.

Public-source service review

Public-source writing. No personal testing or independent medical review is claimed.

Found’s plans place medical follow-up and lifestyle support beside prescription treatment. For a reader searching for digestive support, the useful starting point is who handles a symptom question, what kind of appointment the plan provides and which costs continue while that question is being resolved. A capsule comparison cannot answer those service questions.

Digestive Side Notes checked Found’s public pricing, medication description, offer terms and billing consent on October 15, 2026. This review concerns those records. We did not enroll, contact a clinician, inspect a dispensed medicine or test whether the program improves digestive symptoms. The commercial supplement placement below belongs to this publication and is separate from Found’s service.

CONTACT: Video or messaging; CARE: Clinical assessment; TERMS: Cycles and renewal. A support tool does not establish a clinical response time.
A support tool does not establish a clinical response time.

What kind of follow-up is being offered?

Found’s pricing page describes two ways of receiving care. Insurance plans require synchronous video visits billed through insurance, with patient cost sharing on top of the plan charge. Cash-pay care is described as text-based in most cases. Both are advertised as access to Found-affiliated clinicians, but the communication format and payment arrangement differ.

That distinction matters when choosing where to bring a concern. Ask how to reach the clinical team between planned visits, how quickly a message is normally reviewed, and when the service directs someone to local or urgent care. The ability to send a message at any time is not evidence that a licensed clinician answers immediately. We did not measure response times or appointment availability.

Nutrition and coaching have a defined role

The offer terms describe coaching, app tools and community access among plan features. The pricing page also promotes Aimee, an AI companion. These features should be identified individually when asking what support is included. An automated companion or community discussion does not establish that a symptom has been assessed by a medical professional.

A useful nutrition conversation might start with the reader’s current food pattern, the timing of a concern and a complete supplement label. It should not start with an assumption that everyone using a GLP-1 medicine needs the same fiber powder or probiotic. Our care-team note explains how to prepare a focused conversation without turning a product review into a diagnosis or treatment plan.

The starting price depends on the agreement

Found advertises compounded-plan starting figures of $99 with insurance or $169 cash pay, described as monthly prices based on longer plans paid upfront. The same pricing page shows higher one-month starting figures of $199 and $289. The offer documents use four-week, 28-day billing cycles. A four-week period is shorter than a calendar month, so “monthly” wording alone is insufficient for budgeting.

Request the exact amount due today, the number of covered cycles, the first renewal date and any separate visit charges. Do not calculate a calendar-year total merely by multiplying a headline by twelve. The public offer’s term labels and cycle descriptions need to be read together, and the actual enrollment agreement should settle the payment schedule. We did not complete checkout to verify an individual total.

Included medicine depends on the plan

Found’s offer document distinguishes compounded GLP-1 plans from branded GLP-1 access plans and non-GLP-1 generic plans. A medication-inclusive claim for one arrangement should not be transferred to another. Branded GLP-1 medicine costs are listed separately from membership, and laboratory charges may also be outside the quoted plan price.

The word “insurance” on a plan does not by itself mean that an insurer pays for the compounded medicine. It can refer to billing clinical care through insurance while other charges remain the patient’s responsibility. Found’s billing consent addresses separate financial obligations. Ask for a written breakdown that identifies the clinical service, medicine, pharmacy and any labs instead of accepting a single unexplained total.

Keep compounding and symptom evidence separate

Found’s compounded semaglutide page describes prescribing and pharmacy fulfillment and acknowledges that the preparation is not FDA-approved. FDA explains that compounded drugs do not receive its premarket review for safety, effectiveness and quality. The agency says they should be used only when a patient’s medical needs cannot be met by an approved drug.

That regulatory distinction does not establish a personal treatment choice, and this review supplies no dose or switching instructions. Similarly, a provider’s reported weight-loss results do not prove that a particular supplement manages nausea, fullness or constipation. Our nausea-claims note keeps a marketing claim separate from the question a clinician needs to assess. Severe or persistent symptoms deserve medical attention; waiting for a product order is not a care plan.

Clarify cancellation before the first renewal

The offer terms recommend canceling or pausing at least 48 hours before renewal and describe renewal payments as nonrefundable. They also describe an initial membership refund in relation to three days after purchase and the first medical consultation. The wording joins those conditions and a subsequent nonrefundability statement imperfectly, so we would ask support to confirm the applicable cutoff in writing rather than promise that one condition always extends the other.

Medicines and lab kits become nonreturnable and nonrefundable once dispensed or shipped under those terms. Being disqualified from every treatment option is described differently from being declined for a preferred medicine while other options remain. The billing consent separately lists a $30 missed-visit fee for failing to attend or canceling with less than 24 hours’ notice. Confirm which policy applies to the actual appointment and plan.

Take one complete question to the right person

Before joining, identify the clinical contact, the type of follow-up, the payment period and the effective cancellation date. Bring symptom and medication questions to the prescribing team, nutrition questions to the appropriate qualified professional, and charge disputes to billing. Keep the answers with the source document or confirmation that supports them.

Our subscription-cost note can help organize a separate supplement purchase, while conversation cards preserve product facts and questions without collecting health information. Neither tool determines eligibility for Found or validates a supplement for use during prescription treatment. The review’s conclusion is a set of documented service boundaries, with individual access, costs and outcomes still requiring confirmation.

Sources and limits

Access dates appear with each source. An access date is separate from the source’s clinical review or label revision date.

  1. Found — plans and pricing

    Provider offer. Checked 2026-10-15. Care format and advertised prices; plan selection, copays and personal eligibility not verified.

  2. Found — offer and refund terms

    Provider terms. Checked 2026-10-15. Plan inclusions, 28-day cycles and cancellation/refund wording; initial refund cutoff needs plan-specific confirmation.

  3. Found — payment and billing consent

    Provider billing agreement. Checked 2026-10-15. Financial responsibility and missed-visit fee; no individual claim or bill examined.

  4. Found — compounded semaglutide description

    Provider medication page. Checked 2026-10-15. Advertised prescribing and follow-up; compounded preparation is not FDA-approved; no outcomes or batch testing.

  5. FDA — concerns with unapproved GLP-1 drugs

    Regulator guidance. Checked 2026-10-15. Compounding review and safety boundaries; not an evaluation of Found or an individual treatment choice.